FDA Leadership Changes Tune On Pediatric Priority Review Voucher Benefit

As the reauthorization deadline nears, CDER and CBER leaders stressed that sunsetting the program would hurt pediatric rare disease development, while endorsing a new Democrat-proposed stick for rare disease research.